|
NOTE 11:- SHARE-BASED PAYMENT TRANSACTIONS
On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the “2013 Plan”). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of 10 years.
Under the Company’s 2013 Plan, in July
2022, the Company’s Board of Directors approved to increase number of ordinary shares reserved for issuance to 35,000,000. As of
December 31, 2022, 8,023,000 shares available for future grant under the 2013 Plan.
| |
b. |
Expenses recognized in the financial statements: |
| |
|
Year ended December 31, |
|
| |
|
2022 |
|
|
2021 |
|
|
2020 |
|
| |
|
|
|
|
|
|
|
|
|
| Research and development expenses |
|
$ |
137 |
|
|
$ |
200 |
|
|
$ |
159 |
|
| General and administrative expenses |
|
|
126 |
|
|
|
266 |
|
|
|
158 |
|
| |
|
|
263 |
|
|
|
466 |
|
|
|
317 |
|
| |
c. |
Share-based payment transactions granted by the Company: |
The fair value of the Company’s
share options granted was estimated using the binomial option pricing model using the following range assumptions:
| Description |
|
2022 |
|
|
2021 |
|
|
2020 |
|
| |
|
|
|
|
|
|
|
|
|
| Risk-free interest rate |
|
|
1.41%-3.08% |
|
|
|
1.22-1.28% |
|
|
|
0.93-2.40% |
|
| Expected volatility |
|
|
83.98%-84.26% |
|
|
|
82.40-82.43% |
|
|
|
65.63-78.77% |
|
| Dividend yield |
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
| Contractual life |
|
|
10 |
|
|
|
10 |
|
|
|
9.83 - 10 |
|
| Early Exercise Multiple (Suboptimal Factor) |
|
|
2.5-3 |
|
|
|
3 |
|
|
|
2.5 - 3 |
|
| Exercise price (NIS) |
|
|
0.25 |
|
|
|
0.25-0.253 |
|
|
|
0.25 - 2.344 |
|
| |
|
Movement during the year: |
The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the year ended December 31, 2022 and related information:
| |
|
Number of
options |
|
|
Weighted
average
exercise
price |
|
|
Weighted
average
remaining
contractual
terms (in years) |
|
|
Aggregate
intrinsic
value |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding at December 31, 20221 |
|
|
18,422,700 |
|
|
|
0.18 |
|
|
|
8.45 |
|
|
|
- |
|
| Grants |
|
|
8,750,000 |
|
|
|
0.07 |
|
|
|
|
|
|
|
|
|
| Forfeited/expired |
|
|
(170,500 |
) |
|
|
0.54 |
|
|
|
- |
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding at December 31, 2022 |
|
|
27,002,200 |
|
|
|
0.13 |
|
|
|
7.14 |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vested and expected to vest at December 31, 2022 |
|
|
27,002,200 |
|
|
|
0.13 |
|
|
|
7.14 |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable at December 31, 2022 |
|
|
11,071,575 |
|
|
|
0.21 |
|
|
|
7.18 |
|
|
|
- |
|
| | d. | The weighted average remaining contractual life for the shares subject to options outstanding as of December 31, 2022, 2021 and 2020 was 6.96 years, 8.45 years and 6.98 years, respectively. |
| | e. | The weighted average grant date fair value in 2022 was $0.02 and in 2021 was $0.18 and the remaining compensation costs not yet recognized as of December 31, 2022 is $230 with a weighted average period of 2.73 years to recognize these expenses. |
|